VLA15 with Alum + VLA15 without Alum
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lyme Borreliosis, Nervous System
Conditions
Lyme Borreliosis, Nervous System
Trial Timeline
Jan 31, 2017 → Jan 16, 2019
NCT ID
NCT03010228About VLA15 with Alum + VLA15 without Alum
VLA15 with Alum + VLA15 without Alum is a phase 1 stage product being developed by Pfizer for Lyme Borreliosis, Nervous System. The current trial status is completed. This product is registered under clinical trial identifier NCT03010228. Target conditions include Lyme Borreliosis, Nervous System.
What happened to similar drugs?
0 of 3 similar drugs in Lyme Borreliosis, Nervous System were approved
Approved (0) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03010228 | Phase 1 | Completed |
Competing Products
8 competing products in Lyme Borreliosis, Nervous System
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1975 | Moderna | Phase 2 | 0 |
| VLA15 + Placebo | Pfizer | Phase 2 | 35 |
| VLA15 + Placebo | Pfizer | Phase 3 | 47 |
| VLA15 + Placebo | Pfizer | Phase 2 | 35 |
| VLA15 | Pfizer | Phase 3 | 44 |
| VLA15 | Pfizer | Phase 3 | 40 |
| VLA15 + Placebo | Pfizer | Phase 2 | 35 |
| Multivalent recombinant OspA Lyme Borreliosis Vaccine + Multivalent recombinant OspA Lyme Borreliosis Vaccine + Multivalent recombinant OspA Lyme Borreliosis Vaccine | Baxter | Phase 1/2 | 29 |